[2] [3] This includes oral hormonal contraceptives, where women should be advised to use a non-oral contraceptive method or add a barrier method for 4 weeks after initiation and each dose escalation
Data from randomized controlled trials suggest that withdrawing either glucagon-like peptide-1 (GLP-1) receptor agonists or dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonists leads to a substantial regain of lost weight
112,113 Furthermore, lifestyle factors may enhance metabolic risks, exacerbating the likelihood of biliary disease in susceptible individuals
GLP-1glucagon-like peptide-1 glucagon , GIPglucose-dependent insulinotropic polypeptide
Conversely, studies not directly relevant to the topic, publications in languages other than English, and those inaccessible via reputable scientific databases were excluded from the review